Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Uniti Group Inc. to Participate at the J.P. Morgan 2026 U.S. Opportunities Forum (GlobeNewswire EN) +++ UNITI Aktie +3,91%

MYRIAD GENETICS Aktie

>MYRIAD GENETICS Performance
1 Woche: -9,0%
1 Monat: +34,9%
3 Monate: +104,4%
6 Monate: +28,7%
1 Jahr: -0,9%
laufendes Jahr: +2,8%
>MYRIAD GENETICS Aktie
Name:  MYRIAD GENETICS DL-,01
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US62855J1043 / 897518
Symbol/ Ticker:  MYD (Frankfurt) / MYGN (NASDAQ)
Kürzel:  FRA:MYD, ETR:MYD, MYD:GR, NASDAQ:MYGN
Index:  -
Webseite:  https://myriad.com/
Profil:  Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company that develops and commercializes genetic tests to support disease risk assessment, diagnosis, treatment selection, and patient management. Its current portfolio focuses o..
>Volltext..
Marktkapitalisierung:  513.33 Mio. EUR
Unternehmenswert:  603.72 Mio. EUR
Umsatz:  719.08 Mio. EUR
EBITDA:  -36.91 Mio. EUR
Nettogewinn:  -100.38 Mio. EUR
Gewinn je Aktie:  -1.07 EUR
Schulden:  187.66 Mio. EUR
Liquide Mittel:  102.7 Mio. EUR
Operativer Cashflow:  6.86 Mio. EUR
Bargeldquote:  0.88
Umsatzwachstum:  -0.11%
Gewinnwachstum:  70.61%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  MYRIAD GENETICS
Letzte Datenerhebung:  06.11.26
>Kennzahlen
Aktien/ Unternehmen:
Aktien: 95.65 Mio. St.
Frei handelbar: 92.63%
Rückkaufquote: -0.59%
Mitarbeiter: 2700
Umsatz/Mitarb.: 0.27 Mio. EUR
Analysten:
Analystenrating: Neutral
Kursziel: -14.34%
Bewertung:
KGV: -
KGV lG: -
KUV: 0.68
KBV: 1.95
PEG-Ratio: -
EV/EBITDA: -
Rentabilität:
Bruttomarge: 65.1%
Gewinnmarge: -13.96%
Operative Marge: -11.22%
Managementeffizenz:
Gesamtkaprendite: -17.11%
Eigenkaprendite: -32.54%
>Peer Group
Gesundheit, Onkologie/ Krebs- Behandlung, Zell- & Gentherapie/ Gentechnik/ Erbkrankheiten
 
05.11.26 - 19:36
Myriad Genetics (MYGN) Q3 2026 Earnings Call Transcript (Fool)
 
Myriad is selling its Prenatal Health unit to Labcorp for $210 million in cash....
05.11.26 - 03:15
Myriad Genetics (MYGN) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
 
Myriad (MYGN) delivered earnings and revenue surprises of +35.29% and +7.48%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?...
04.11.26 - 22:30
Myriad Genetics Non-GAAP EPS of -$0.11 beats by $0.09, revenue of $202.7M beats by $11.37M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
02.11.26 - 22:06
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences (GlobeNewswire EN)
 
Myriad to participate in UBS Global Healthcare Conference, 2026 Stephens Investment Conference and 38th Annual Piper Sandler Healthcare Conference....
22.10.26 - 15:06
Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers (GlobeNewswire EN)
 
Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers...
20.10.26 - 17:30
Myriad Genetics-Aktie schießt nach 210-Millionen-Dollar-Verkauf der Pränatalsparte um 36 % nach oben (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
20.10.26 - 17:30
Myriad Genetics stock surges on $210M prenatal unit sale (Investing.com)
 
Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...
20.10.26 - 16:00
Labcorp To Buy Myriad Genetics′ Prenatal Testing Business For $210 Mln (AFX)
 
WASHINGTON (dpa-AFX) - Laboratory services provider LabCorp Holdings Inc. (LH) announced on Tuesday that it has agreed to acquire the Prenatal Health testing business of molecular diagnostics comp......
20.10.26 - 15:18
Myriad Genetics: Kurssprung nach Verkauf des Pränatalbereichs an Labcorp für 210 Millionen Dollar (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
20.10.26 - 14:33
Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp (GlobeNewswire EN)
 
Myriad Genetics and Labcorp have entered into a definitive agreement for Myriad to sell its Prenatal Health testing business to Labcorp....
15.10.26 - 22:06
Myriad Genetics to Release Third Quarter 2026 Financial Results on November 4, 2026 (GlobeNewswire EN)
 
Myriad Genetics to Release Third Quarter 2026 Financial Results on November 4, 2026...
13.10.26 - 13:06
Paul J. Diaz Elected to Merck & Co., Inc., Rahway, N.J., USA Board of Directors (Business Wire)
 
RAHWAY, N.J.--(BUSINESS WIRE)--Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Paul J. Diaz, managing partner at Cressey & Company, will join the Company's Board of Directors effective Nov. 1, 2026. He will stand for election by the company's shareholders in May 2027. With the addition of Mr. Diaz, the Merck board will consist of 14 members. “We are pleased to welcome Paul Diaz to our Board. Paul brings extensive leadership and business expertise in the healthcare industry, and we look forward to his contributions and insights,” said Rob Davis, chairman and chief executive officer. Mr. Diaz is a managing partner at Cressey & Company, a private investment firm focused on investing in and cultivating high-quality health care firms. He previously served as president and chief executive officer of Myriad Genetics, Inc., a leading genetic testing and precision medicine company. Before that, he served as president and chief executiv...
08.10.26 - 15:03
Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology (GlobeNewswire EN)
 
Myriad announces new collaboration to advance prostate cancer-specific genomic instability score (PrGIS) technology to support precision oncology and CDx....
10.09.26 - 18:12
Myriad Genetics unter Druck: Fokus auf Krebstests soll Wende bringen (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
01.09.26 - 19:48
Myriad Genetics downgraded at Piper Sandler on structural challenges (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
01.09.26 - 13:54
Piper Sandler stuft Myriad Genetics drastisch ab – Aktie bricht ein (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
10.08.26 - 16:09
Myriad Genetics (MYGN) Securities Investigation Notice - Levi & Korsinsky (PR Newswire)
 
Myriad Genetics reported Q2 2026 revenue of approximately $190.7 million against consensus of roughly $206-208 million, then cut full-year revenue guidance by about $90 million at the midpoint and suspended adjusted EBITDA guidance. Levi & Korsinsky is investigating potential securities......
04.08.26 - 16:09
MYGN SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Myriad Genetics (PR Newswire)
 
Myriad Genetics guided to adjusted gross margin of 68%-69% for 2026. Months later, the Company cut its revenue outlook, suspended EBITDA guidance, and MYGN shareholders absorbed the loss. NEW YORK, Aug. 4, 2026 /PRNewswire/ -- Myriad Genetics (NASDAQ: MYGN) investors are sitting on losses......
04.08.26 - 00:16
Myriad Genetics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Myriad Genetics (MYGN) (PR Newswire)
 
On May 5, 2026, Myriad Genetics management reaffirmed full-year revenue of $860-$880 million. Just three months later, the Company cut guidance to $770-$790 million and adjusted EBITDA guidance was suspended -- and MYGN shareholders absorbed the loss. NEW YORK, Aug. 3, 2026 /PRNewswire/......
31.07.26 - 01:45
Myriad Genetics (MYGN) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
 
Myriad (MYGN) delivered earnings and revenue surprises of -733.33% and -7.12%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Müßiggang ist des Teufels Ruhebank. - Sprichwort Deutschland
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!